title: Different effects of two alpha-glucosidase inhibitors, acarbose and voglibose, on serum 1,5-anhydroglucitol (1,5AG) level.
abstract: Serum 1,5-anhydroglucitol (1,5AG) is a useful glycemic marker in the control of diabetes; however, treated with alpha-glucosidase inhibitors (alpha-GIs), acarbose (Aca) and voglibose (Vog), it tends to show the discrepancy between serum 1,5AG and related glucose levels. Twenty patients were randomly assigned to adding Aca or Vog to the current treatment. We measured serum 1,5AG levels and other parameters of diabetic control before, 2 and 4 weeks after the alpha-GI treatment. We also measured urinary 1,5AG levels using gas chromatography/mass spectrometry (GC/MS). Glycated albumin, Hb(A1c), and fasting plasma glucose (FPG) levels were significantly decreased after 2 and 4 weeks of treatment, and the changes were similar in the two groups. Despite the similar urinary excretion of 1,5AG and other glycemic parameters, serum 1,5AG level was significantly lower in the Aca group than in the Vog group (3.4+/-0.5 vs. 7.9+/-1.2 microg/ml, P<.005; mean+/-S.E.) at the period of 4 weeks. Even in the same glycemic level, the less increase of serum 1,5AG after treatment with Aca might be due to a reduction of intestinal 1,5AG absorption via inhibition of alpha-amylase that features Aca.
authors.affiliation: Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, 1-1, Hongo 2-chome, Bunkyo-ku, Tokyo 113-8421, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Watanabe
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Uchino
authors.forename: Chie
authors.initials: C
authors.lastname: Ohmura
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Tanaka
authors.forename: Tomio
authors.initials: T
authors.lastname: Onuma
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Kawamori
mesh_terms: D020909:Acarbose / Q000494:pharmacology* / Q000627:therapeutic use; D001786:Blood Glucose / Q000737:chemistry / Q000187:drug effects; D003847:Deoxyglucose / Q000097:blood / Q000378:metabolism* / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D005544:Forecasting; D006442:Glycated Hemoglobin / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D017127:Glycation End Products, Advanced; D065089:Glycoside Hydrolase Inhibitors; D006029:Glycosuria; D006801:Humans; D007294:Inositol / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D012709:Serum Albumin / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013997:Time Factors; D000520:alpha-Glucosidases / Q000494:pharmacology* / Q000627:therapeutic use; D000093423:Glycated Serum Albumin
chemical_list: D020909:Acarbose; D001786:Blood Glucose; D003847:Deoxyglucose; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D065089:Glycoside Hydrolase Inhibitors; D007294:Inositol; D012709:Serum Albumin; D013453:Sulfonylurea Compounds; D000520:alpha-Glucosidases; D000093423:Glycated Serum Albumin; C006584:1,5-anhydroglucitol; C102817:voglibose